logo
Twitter
Discord
Email
logo
HCA Healthcare, Inc.

HCA Healthcare, Inc.

NYSE•HCA
CEO: Mr. Samuel N. Hazen
Sector: Healthcare
Industry: Medical - Care Facilities
Listing Date: 2011-03-10
HCA Healthcare, Inc., through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, it operates behavioral hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.
Contact Information
One Park Plaza, Nashville, TN, 37203, United States
615-344-9551
www.hcahealthcare.com
Market Cap
$113.77B
P/E (TTM)
17.8
16
Dividend Yield
0.6%
52W High
$520.00
52W Low
$289.98
52W Range
78%
Rank23Top 6.9%
6.2
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$19.16B+9.57%
4-Quarter Trend

EPS

-$10.54-313.36%
4-Quarter Trend

FCF

$3.13B+34.60%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Nine Month Revenue Growth Revenues reached $56.087B USD, marking a 7.2% increase over prior nine months period ending September 30, 2025.
Net Income Improvement Net income attributable to HCA grew 13.5% to $4.906B USD for the nine months, driving diluted EPS to $20.23 USD.
Strong Operating Cash Flow Cash provided by operations totaled $10.277B USD, significantly up from $7.955B USD last year for the nine months.

Risk Factors

Regulatory Reimbursement Uncertainty Potential Medicare reimbursement cuts up to 4% in early 2026 loom due to Pay-As-You-Go Act sequestration requirements.
Widening Stockholder Deficit Retained deficit widened to $(5.020)B USD as capital returns, including $7.509B in repurchases, exceeded cumulative earnings.
Uninsured Care Cost Increase Estimated cost of total uncompensated care for nine months reached $3.359B USD, slightly up from $3.220B USD in 2024.

Outlook

Capital Expenditure Projections Planned capital expenditures are projected around $5.0B USD for the full year 2025, financed by internal funds and borrowing.
Debt Refinancing Capacity Management intends to utilize $8.0B senior unsecured credit facility capacity to refinance short-term commercial paper borrowings.
Policy Impact Resiliency Management is developing resiliency plans to offset potential financial impacts from OBBBA legislation and evolving health policy changes.

Peer Comparison

Revenue (TTM)

CVS Health CorporationCVS
$394.08B
+6.8%
McKesson CorporationMCK
$387.09B
+17.2%
The Cigna GroupCI
$268.13B
+15.3%

Gross Margin (Latest Quarter)

Vertex Pharmaceuticals IncorporatedVRTX
86.5%
+0.7pp
SanofiSNY
74.1%
+2.9pp
GSK plcGSK
73.6%
+3.5pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
MDT$129.25B27.19.8%31.9%
SNY$117.63B11.112.4%16.8%
VRTX$114.10B30.919.6%7.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.6%
Moderate Growth
4Q Net Income CAGR
5.2%
Profitability Improving
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Jan 23, 2026
|
EPS:$7.39
|
Revenue:$19.66B
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Oct 30, 2025|
    Revenue: $19.16B+9.6%
    |
    EPS: $-10.54-313.4%
    Miss
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 4, 2025|
    Revenue: $18.61B+6.4%
    |
    EPS: $6.91+23.4%
    Beat
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 1, 2025|
    Revenue: $18.32B+5.7%
    |
    EPS: $6.52+7.9%
    Beat
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 14, 2025|
    Revenue: $70.60B+8.7%
    |
    EPS: $22.27+15.7%
    Beat
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Oct 31, 2024|
    Revenue: $17.49B+7.9%
    |
    EPS: $4.94+24.1%
    Meet
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Jul 29, 2024|
    Revenue: $17.49B+10.3%
    |
    EPS: $5.60+28.7%
    Beat
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 2, 2024|
    Revenue: $17.34B+11.2%
    |
    EPS: $6.04+22.8%
    Beat
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 16, 2024|
    Revenue: $64.97B+7.9%
    |
    EPS: $19.24-1.0%
    Beat